헤파린 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 용도별, 투여 경로별, 최종 용도별, 지역별 부문, 경쟁(2020-2030년)

Heparin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Route of Administration, By End Use By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,701,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,191,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,914,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

헤파린 세계 시장 규모는 2024년 64억 8,000만 달러에 달했고, 예측 기간 동안 2030년까지 연평균 5.96%의 견조한 성장세를 보일 것으로 예상됩니다.

세계 헤파린 시장은 제약 및 헬스케어 산업의 중요한 부문으로 혈전성 질환의 예방 및 치료에 있어 매우 중요한 역할을 하고 있습니다. 천연 유래 항응고제인 헤파린은 주로 심부정맥혈전증(DVT), 폐색전증(PE), 기타 응고 장애 등의 예방 및 관리에 사용됩니다. 이 시장은 심혈관 질환 발병률 증가, 고령화 인구 증가, 전 세계 외과 수술 증가 등을 배경으로 최근 몇 년간 큰 성장세를 보이고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	64억 8,000만 달러
시장 규모 : 2030년	91억 달러
CAGR : 2025-2030년	5.96%
급성장 부문	저분자 헤파린
최대 시장	북미

시장 성장 촉진요인

용도 확대

시장의 과제

규제 강화 및 컴플라이언스

주요 시장 동향

용도 확장

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 헤파린 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(저분자량 헤파린(LMWH), 초저분자량 헤파린(ULMWH))
  • 용도별(정맥혈전 색전증, 관상동맥 질환, 신장기능 장애, 심방세동, 기타)
  • 투여 경로별(정맥내, 피하)
  • 용도별(병원 및 진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 유형별
  • 용도별
  • 투여 경로별
  • 최종 용도별
  • 지역별

제5장 아시아태평양의 헤파린 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 용도별
  • 투여 경로별
  • 최종 용도별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 헤파린 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 헤파린 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제8장 남미의 헤파린 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 헤파린 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이집트

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 헤파린 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• GlaxoSmithKline plc(GSK)
• Pfizer Inc.
• Sanofi AG
• Dr. Reddy's Laboratories Ltd.
• Aspen Holdings
• B. Braun Medical Inc.
• Fresenius SE & Co. KGaA
• Novartis AG
• Sandoz(Novartis AG)

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Heparin Market was valued at USD 6.48 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 5.96% through 2030. The global heparin market is a vital segment of the pharmaceutical and healthcare industry, playing a pivotal role in the prevention and treatment of thrombotic disorders. Heparin, a naturally occurring anticoagulant, is primarily used to prevent and manage conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and other clotting disorders. This market has witnessed significant growth in recent years, driven by a rising incidence of cardiovascular diseases, a growing aging population, and increasing surgical procedures globally.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.48 Billion
Market Size 2030	USD 9.10 Billion
CAGR 2025-2030	5.96%
Fastest Growing Segment	Low Molecular Weight Heparin
Largest Market	North America

Key Market Drivers

Expanding Applications

Expanding applications of heparin have emerged as a significant driver behind the growth of the global heparin market. Traditionally known as an anticoagulant, heparin has ventured into new therapeutic domains, broadening its market potential and fostering increased demand. Researchers and healthcare professionals have recognized its diverse properties, leading to its use in several medical conditions beyond its original scope. For instance, an October 2023 NCBI article highlighted that in the U.S., someone requires a blood transfusion every two seconds, playing a crucial role in saving lives. With only 62 out of 171 countries relying entirely on voluntary unpaid blood donations, maintaining a sufficient and safe blood supply remains a challenge. As blood transfusion efforts expand, the demand for heparin is expected to rise, supporting successful procedures and enhancing patient outcomes.

One of the key areas where heparin's applications have expanded is in the treatment of cancer. Heparin's anti-inflammatory and anti-angiogenic properties make it a promising candidate for cancer therapy. It has been utilized in cancer research to inhibit the growth of blood vessels that supply tumors, a process known as angiogenesis. By impeding angiogenesis, heparin helps curb the tumor's blood supply, potentially limiting its growth and spread. As research in this area continues, heparin-based cancer therapies are gaining traction, contributing to the growth of the heparin market.

Heparin-coated medical devices have gained prominence in the healthcare industry. These devices, such as catheters and stents, are designed with a heparin-coated surface to reduce the risk of thrombosis and infection. Heparin's anticoagulant properties, when applied to medical equipment, help prevent blood clot formation and improve the safety of various medical procedures. As healthcare facilities increasingly adopt these advanced technologies, the demand for heparin-coated devices is on the rise, further fueling the expansion of heparin's applications and market growth.

Key Market Challenges

Regulatory Scrutiny and Compliance

The global heparin market, a crucial component of the pharmaceutical and healthcare industry, faces significant challenges stemming from rigorous regulatory scrutiny and compliance requirements imposed by health authorities worldwide. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, have established stringent guidelines to safeguard the safety and quality of heparin products. These regulations are essential to protect patient health and prevent adverse events linked to contaminated or substandard heparin. However, compliance with these multifaceted guidelines is a significant challenge for manufacturers and suppliers.

The complexity of heparin production, which involves sourcing raw materials from porcine intestines or other animal sources and then processing them into pharmaceutical-grade products, necessitates adherence to Good Manufacturing Practices (GMP) at every stage. Ensuring the purity and safety of heparin requires extensive quality control measures, traceability systems, and rigorous documentation. In the pursuit of compliance, companies must invest substantially in infrastructure, skilled personnel, and advanced technologies. This investment raises production costs, which can ultimately impact the pricing and affordability of heparin-based therapies for patients.

Key Market Trends

Expanding Applications

Expanding applications of heparin have emerged as a significant driver behind the growth of the global heparin market. Traditionally known as an anticoagulant, heparin has ventured into new therapeutic domains, broadening its market potential and fostering increased demand. Researchers and healthcare professionals have recognized its diverse properties, leading to its use in several medical conditions beyond its original scope.

One of the key areas where heparin's applications have expanded is in the treatment of cancer. Heparin's anti-inflammatory and anti-angiogenic properties make it a promising candidate for cancer therapy. It has been utilized in cancer research to inhibit the growth of blood vessels that supply tumors, a process known as angiogenesis. By impeding angiogenesis, heparin helps curb the tumor's blood supply, potentially limiting its growth and spread. As research in this area continues, heparin-based cancer therapies are gaining traction, contributing to the growth of the heparin market.

Key Market Players

• GlaxoSmithKline plc (GSK)
• Pfizer Inc.
• Sanofi AG
• Dr. Reddy's Laboratories Ltd.
• Aspen Holdings
• B. Braun Medical Inc.
• Fresenius SE & Co. KGaA
• Novartis AG
• Sandoz (Novartis AG)

Report Scope:

In this report, the Global Heparin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Heparin Market, By Application:

• Venous Thromboembolism
• Coronary Artery Disease
• Renal Impairment
• Atrial Fibrillation
• Others

Heparin Market, By Route of Administration:

• Intravenous
• Subcutaneous

Heparin Market, By End Use:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Heparin Market, By Type:

• Low Molecular Weight Heparin (LMWH)
• Ultra-Low Molecular Weight Heparin (ULMWH)

Heparin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heparin Market.

Available Customizations:

Global Heparin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Heparin Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH))
  • 4.2.2. By Application (Venous Thromboembolism, Coronary Artery Disease, Renal Impairment, Atrial Fibrillation, Others)
  • 4.2.3. By Route of Administration (Intravenous, Subcutaneous)
  • 4.2.4. By End Use (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Application
  • 4.3.3. By Route of Administration
  • 4.3.4. By End Use
  • 4.3.5. By Region

5. Asia Pacific Heparin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Application
  • 5.2.3. By Route of Administration
  • 5.2.4. By End Use
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Heparin Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Application
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By End Use
  • 5.3.2. India Heparin Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Application
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By End Use
  • 5.3.3. Australia Heparin Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Application
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By End Use
  • 5.3.4. Japan Heparin Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Application
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By End Use
  • 5.3.5. South Korea Heparin Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Application
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By End Use

6. Europe Heparin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Route of Administration
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Heparin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End Use
  • 6.3.2. Germany Heparin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End Use
  • 6.3.3. Spain Heparin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End Use
  • 6.3.4. Italy Heparin Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By End Use
  • 6.3.5. United Kingdom Heparin Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By End Use

7. North America Heparin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Route of Administration
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Heparin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End Use
  • 7.3.2. Mexico Heparin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End Use
  • 7.3.3. Canada Heparin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End Use

8. South America Heparin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Route of Administration
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Heparin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End Use
  • 8.3.2. Argentina Heparin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End Use
  • 8.3.3. Colombia Heparin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End Use

9. Middle East and Africa Heparin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Route of Administration
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Heparin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End Use
  • 9.3.2. Saudi Arabia Heparin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End Use
  • 9.3.3. UAE Heparin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End Use
  • 9.3.4. Egypt Heparin Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Application
      • 9.3.4.2.3. By Route of Administration
      • 9.3.4.2.4. By End Use

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Heparin Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. GlaxoSmithKline plc (GSK)
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Sanofi AG
• 14.4. Dr. Reddy's Laboratories Ltd.
• 14.5. Aspen Holdings
• 14.6. B. Braun Medical Inc.
• 14.7. Fresenius SE & Co. KGaA
• 14.8. Novartis AG
• 14.9. Sandoz (Novartis AG)

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료